Following the success of canakinumab in the treatment of autoinflammatory diseases as sJIA [24, 25] and monogenic autoinflammatory diseases [26–28], and the low efficacy in recurrent pericarditis, the anti-IL-1 beta blockade is not considered the target treatment in MIS-C. Here, IL1B is linked to pericarditis.